MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Multiple Sclerosis (MS)
TG Therapeutics, Inc. (NASDAQ: TGTX)*
Organization & Developments: TG Therapeutics
Parents
TG Therapeutics, Inc. (NASDAQ: TGTX)*
Children
*A small-cap biotech company that is dedicated to the study of B-cells and B-cell diseases
*TG Therapeutics, a biopharmaceutical company, develops agents for the treatment of hematologic malignancies and autoimmune disorder
2016: Biotech Forum Daily Digest: Bear Market Officially Over, Bristol-Meyers Squibb's Big Miss, Spotlight on TG Therapeutics (NASDAQ:TGTX)
2017: Biotech Forum Daily Digest: TG Therapeutics Continues To Soar, Buyout Rumors Surround Global Blood Therapeutics (GBT)
2017: TG Therapeutics: Oncology Concern Looks Like Solid Bet In 2018 - TG Therapeutics, Inc. (NASDAQ:TGTX)
2018: Revisiting TG Therapeutics_seekingalpha.com
2018: TG Therapeutics Is Worth A Look Before Phase 3 Combination Cancer Data
2018: TG Therapeutics: Further Appreciation In 2018 Likely_seekingalpha.com
2019: Biotech Analysis Central Preview Series: TG Therapeutics_seekingalpha.com
2019: Revisiting TG Therapeutics_seekingalpha.com
2019: TG Therapeutics Lines Up Potential Accelerated Approval For Cancer Drug_seekingalpha.com
2019: TG Therapeutics_Targeting a 45% Return on this Small Oncology Concern_gallery.mailchimp.com
2019: TG Therapeutics’ shares jump as umbralisib wins FDA’s breakthrough status – Endpoints News
2020: TG Therapeutics: Excellent, Multi-Modal Opportunity
2020: TG Therapeutics: What's Next After The MS Conquest?
2021: TG Therapeutics: Great Set Of Catalysts, Approvals This Year And Next
2021: The Take On TG Therapeutics
2022: TG Therapeutics withdraws U2 application — and its component's approvals — one week before adcomm
2022: TG Therapeutics: Elucidating The Upcoming Binary_seekingalpha.com
2022: TG Therapeutics: Ublituximab Could Achieve $1 Billion In Annual Sales By Year-End 2024_ seekingalpha.com
2022: TG Therapeutics: We Are Just Hanging In There_seekingalpha.com
2022: TG Therapeutics: Would Santa Deliver An Early Present?_ seekingalpha.com
2022: UPDATE: TG disbands cancer program after pulling FDA request for U2 combo therapy
2023: TG Therapeutics: A Plethora Of Good News, Strong Revenues Expected_seekingalpha.com
2023: TG Therapeutics: Ramifications Of Briumvi Approval_ seekingalpha.com
2023: TG Therapeutics: Things Are Stacking Up Against Briumvi
2023: TG Therapeutics: Trying To Fill The Gap Back To $20_ seekingalpha.com
2023: TG Therapeutics' Stock Surge: Exploring The Factors And Exercising Caution (Rating Upgrade)_ seekingalpha.com
2024: Evaluating TG Therapeutics: Insights From 4 Financial Analysts
2024: IBD 50's TG Therapeutics Rises On Five-Year Data For Multiple Sclerosis Drug
2024: TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
2024: TG Therapeutics Inc (NASDAQ:TGTX) A Bull Case Theory
2024: TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference_seekingalpha.com
2024: TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell
2024: TG Therapeutics Receives Clearance from FDA for Phase 1 Trial in Multiple Sclerosis for Allogeneic CAR-T Azer-Cel
2024: TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
2024: TG Therapeutics: BRIUMVI Development Could Lead To Great Results
2024: TG Therapeutics: Briumvi Growth Story Appears Intact
2024: TG Therapeutics: Briumvi Revenue Soars
2024: TG Therapeutics: Indications Of Slowing Market Growth For Briumvi_ seekingalpha.com
2024: TG Therapeutics: The Cloud Over Briumvi
2024:TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
2025: TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade)
2025: TG Therapeutics: Entering 2025 With Increased Investor Expectations
2025: TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter_seekingalpha.com
2025: TG Therapeutics: Looking For The Stimulus For A Turnaround
2025: TG Therapeutics: Strong Execution Tempered By An Evolving Market
2025: TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst_seekingalpha.com
2026: TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation
Jumps
*Key People: TG Therapeutics
Finance & Acquisitions: TG Therapeutics